The Global Research Collaboration for Infectious Disease Preparedness

CHARTER

Charter................................................................................................................................. 2
Annex I – Members and observers.................................................................................... 7
Annex II – General Operating Principles........................................................................... 9
Annex III – Declaration of interest for GloPID-R Members ............................................ 13
Annex IV – Declaration of interest for GloPID-R experts ............................................... 17
Annex V – Conflict of interest policy for GloPID-R Secretariat ...................................... 20
Annex VI – Conflict of interest policy for GloPID-R ISG ................................................. 23
Charter

**Goal**

The goal of GloPID-R, the Global Research Collaboration for Infectious Disease Preparedness, is to bring together funding organizations investing in research related to new or re-emerging infectious diseases to increase preparedness and facilitate rapid research response to outbreaks with pandemic potential, in order to save lives and limit economic consequences worldwide. GloPID-R represents a **network of research funding organizations**.

**Background**

Worldwide human populations are under threat from new or re-emerging and drug resistant infectious epidemics, which are now not only spreading faster, but also appear to be emerging more frequently than before. Any emerging infectious epidemic or appearance of a new type of drug-resistant infection can strike anywhere anytime in the world; globalization and climate change, urbanization and movements of populations are among the driving factors. The treatment and control are often hampered by delayed diagnosis and the lack of knowledge about the disease, its manifestations, and its treatment and control. Many of these infections are zoonoses, thus necessitating an integrated approach in the human and veterinary fields (‘One Health’ approach). A proper response needs to be quick, flexible, comprehensive and often regional or global and is therefore likely to be beyond the capacity of any single country. Besides being a major threat to human health such epidemics are a severe burden on the global economy with an impact on competitiveness, growth and jobs.

The challenges to conducting meaningful scientific research quickly for new or re-emerging epidemics, referred to herein as ‘research preparedness’, are very complex and shared by researchers in many countries.

In response, the European Commission suggested to the Heads of International (biomedical) Research Funding Organizations (HIRO) the creation of an initiative which would facilitate international collaboration between funders in this area. The European Commission called for the first meeting in 2013 with international research funding organizations from the USA, Canada, China, Australia, the UK, France and Sweden. The Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) initiative was launched at that meeting.

At the second meeting in 2013, GloPID-R was discussed with a wider range of participants including further funding bodies, representatives from additional interested countries and scientific experts.

These consultations led to this Charter, collectively agreed upon in Montréal, on October 1, 2014. The Charter has been regularly updated according to GloPID-R developments such as the secretariat, Industry stakeholder group, operational tools and procedures. In 2019, the GloPID-R strategy has been revised and validated by the General Assembly in Tokyo, on May 14, which led to updating the Charter.
**Objectives**

GloPID-R aims to invest in research related to new or re-emerging infectious diseases in order to increase preparedness and facilitate rapid research response to outbreaks with pandemic potential.

Accordingly, GloPID-R aims at:

1. Supporting development of research preparedness and readiness activities in order to reinforce rapid response capacities through:
   - Policy development and scientific advice to address scientific, logistical, legal, regulatory, data sharing, ethical and financial challenges to the rapid mounting of such a response
   - Enhanced coordination among stakeholders and partners connect the existing and future research networks in this area.

2. Facilitating rapid and aligned funding of research in an emergency to:
   - ensure a rapid, coordinated and coherent approach of funding agencies
   - identify and leverage potential synergies and complementarities between Members and other stakeholders
   - facilitate exchange of information between funders.

GloPID-R recognizes the crucial role of low-income countries in the global fight against emerging diseases and therefore aims to operate in partnership with these countries.

The concrete steps to achieve the objectives are outlined below under ‘Commitment’.

**GloPID-R** will closely collaborate with public health actors, from national to international (e.g. WHO, OIE) levels, but **its goal is not to coordinate or mount a public health response. It is not a new funding organization, but aims to make the work of its members more effective through collaboration and by jointly addressing the barriers to research preparedness for a rapid response.**

**Membership**

GloPID-R is a global collaboration of funding organizations (network of funders) that establishes and maintains organized relationships with the scientific community, the relevant (pharmaceutical, diagnostics, vaccine and biotech) industries and small and medium enterprises, and public health actors including veterinary services, regulatory agencies and patient groups.
There are currently no fees or dues related to membership in GloPID-R. Members pay their own travel and subsistence expenses related GloPID-R meetings\(^1\).

The list of GloPID-R members is detailed in Annex I.

Participation of companies and industry associations active in the fields of diagnostics, drug and vaccine development and biotechnology relevant to research preparedness for emerging infections is achieved through a specific Industry Stakeholder Group (ISG).

**Commitments**

GloPID-R participants commit to:

- strengthen global cooperation to improve the research response to new and re-emerging infectious disease,
- regularly share information on new funding initiatives and research initiatives in the area of research preparedness for new or re-emerging infectious diseases,
- Establish a common Strategy for research response. This Strategy covers issues within the mandate of GloPID-R, i.e. overcoming the hurdles to a rapid joint research response (such as mechanisms of information exchange, clinical protocols, rapid funding mechanisms etc.).
- implement the Strategy in a coordinated and complementary way through respective funding initiatives. Generally, each GloPID-R member organization shall run its own calls contributing to the shared objectives and agenda,
- facilitate the international collaboration of researchers in the area of research preparedness for emerging infections by:
  - The GloPID R clinical trials network to explore pandemic preparedness together
  - Identify and make better use of clinical infectious disease cohorts for emerging pathogens to allow for their sustainability and capacity building for a rapid research response
- jointly address the logistical, legal, regulatory, ethical, capacity and financial challenges to the rapid and effective mounting of a research response to new or re-emerging infectious diseases (e.g. by streamlining ethical procedures including their ongoing update, standardized protocols/documents and pre-prepared ethical protocols),
- take into account the specific challenges and needs of research preparedness for new or re-emerging infectious diseases in resource-poor settings,
- broaden the circle of participants in GloPID-R through recruitment of additional funding bodies worldwide,

\(^{1}\) If needed and financially possible, the Chairs may only agree to cover the travel and subsistence costs of experts from low- or lower-middle-income countries whose related expertise may be necessary or useful for GloPID-R related activities.
• include the following important stakeholders in the area of research preparedness for new or re-emerging infectious diseases in its deliberations and planning of funding and research initiatives:
  o scientific community,
  o industry and SMEs in the fields of diagnostics, drug and vaccine development and biotechnology relevant to research preparedness for emerging infections,
  o civil society organizations,
  o public health actors including veterinary services at national, regional (e.g. ECDC²) and international (e.g. WHO³, OIE⁴) level,
  o regulatory, legal and ethical institutions and experts as relevant to address the related barriers to a research response;

• communicate and disseminate information on GloPID-R and its objectives.

Governance of GloPID-R

The governance, structure and way of operating of GloPID-R are determined by its members and may be adapted to the evolving needs of the network. Currently, the following governance structure – described in Annex II – is agreed: Each GloPID-R member is assigned in one group (from 1 to 3) and possibly in regional group if relevant.

Members are represented with one vote in the Assembly of GloPID-R members (‘Assembly’). As a general rule, consensus of all Assembly members should be sought for all issues discussed. If consensus cannot be reached, decisions can in exceptional cases be taken with a simple majority. The Assembly elects the Chair and Vice-Chairs of GloPID-R (‘the Chairs’) amongst its members for a duration of 2 years (renewable with no limit of consecutive terms). The Chairs work in close cooperation with Scientific Advisors and with the Committee(s) based on the delegation from the Assembly.

The Assembly meets at least once per year face-to-face and decides on the work programme proposed by the GloPID-R secretariat. In between meetings, decisions can be taken by e-mail or during an audio- or videoconference.

The Assembly decides about the establishment of Committees/Advisory Board and Working Groups.

The Chair invite all members to Assembly meetings, propose the agenda for meetings, propose items for information and decision in between meetings and oversee and direct the work of the secretariat.

---

² European Centre for Disease Prevention and Control
³ World Health Organization
⁴ World Organization for Animal Health
**GloPID-R secretariat**

The task of the secretariat is to provide support to the implementation of GloPID-R in close collaboration with the different committees, Scientific Advisors, Working Groups and other stakeholders.

This includes (i) organizational support to the functioning of the Assembly and the Chairs such as the organization of and reporting on meetings, and information exchange among all members, and assuring administrative management as well as (ii) the direct implementation of actions to achieve GloPID-R’s goal. The latter supporting GloPID-R activities around the facilitation of rapid data sharing, clinical network/cohort sustainability and pandemic preparedness. The secretariat will be engaged in dissemination activities with relevant stakeholder groups and with the public at large (e.g. development of website, communication materials, etc.) as well as involve regions particularly affected by emerging epidemics. The Assembly will adopt the work programme of the Secretariat.

The secretariat will submit regular short updates on its activities to the Chairs.

**Ethics & conflict of interest policy**

All institutions or persons participating in GloPID-R activities agree to participate in good faith and act with the highest ethical and moral standards.

Specifically, conflicts of interest will be avoided based on the following principles:

- All representatives of GloPID-R Members solemnly agree to disclose to other representatives any potential conflict of interest related to his/her institution or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest. All representatives also agree to withdraw from the discussion if such a conflict of interest arises and if requested to do so by the other representatives.

- All representatives of the GloPID-R Industry Stakeholder Group solemnly agree to disclose any potential conflict of interest related to his/her institution or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest. All representatives also agree to withdraw from the discussion if such a conflict of interest arises and if requested to do so by other participants in the discussion or by the GloPID-R Chair.

- All experts called for an advisory role in GloPID-R, such as participation as Scientific Advisor or in specific working groups, are requested to disclose any circumstance that could represent a potential conflict of interest related to the activity in which they will be involved. All experts will therefore sign a declaration of interest to be reviewed according to the principles detailed in the General Operating Principles of Annex II. This declaration of interest is presented in Annex IV.

- All GloPID-R Secretariat members shall abide to the conflict of interest policy presented in Annex V.
Annex I – Members and observers

Members

The following Members have agreed to join the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) initiative and cooperate in the spirit of its Charter:

• Academy of Scientific Research and Technology (Egypt)
• African Academy of Sciences (AAS)
• Bill and Melinda Gates Foundation
• Canadian Institutes of Health Research (CIHR)
• Consejo Nacional de Ciencia y Tecnología (CONACYT, Mexico)
• European Commission – DG Research & Innovation (European Union)
• Fonds National de la Recherche et de l'Innovation pour le Développement (FONDRID, Burkina Faso)
• Fund for Science, Technology and Innovation (FONSTI, Ivory Coast)
• Foreign, Commonwealth and Development Office (FCDO, United Kingdom)
• German Federal Ministry for Education and Research (BMBF)
• Indian Council of Medical Research (ICMR)
• Institut National de la Santé et de la Recherche Médicale (INSERM, France)
• Instituto Butantan (Brazil)
• Instituto Fiocruz (Brazil)
• Instituto de Salud Carlos III (Spain)
• International Development Research Centre (IDRC, Canada)
• Japan Agency for Medical Research and Development (AMED)
• Medical Research Council (United Kingdom)
• Ministry of Health (Italy)
• National Council for Science and Technology (NCST, Rwanda)
• National Health and Medical Research Council (Australia)
• National Research Foundation of Korea (South Korea)
• Netherlands Organisation for Health Research and Development (Netherlands)
• Pasteur Network
• Research Council of Norway (RCN)
• Sao Paulo Research Foundation (FAPESP, Brazil)
• Secretariat of Government of Science, Technology and Productive Innovation (Argentina)
• South African Medical Research Council (SA MRC)
• Swiss National Science Foundation (SNSF)
• National Institute of Health, Department of Medical Sciences (Thailand)
• U.S. Department of Health and Human Services
• Wellcome Trust (United Kingdom)

Observers

• The Coalition for Epidemic Preparedness Innovations (CEPI)
• The ESSENCE on Health Research Initiative (ESSENCE)
• The European and Developing Countries Clinical Trials Partnership (EDCTP)
• The World Health Organization (WHO)

are observers without voting rights in the GloPID-R Assembly.
Annex II – General Operating Principles

I - Membership

1. The GloPID-R initiative is open to funding organizations investing in research related to new or re-emerging infectious diseases and sharing the goal, objectives and commitments expressed in this Charter.

2. All applicants to the GloPID-R initiative are invited to submit a formal application to the Chair. This application should then be submitted for approval to the co-Chairs.

All representatives of GloPID-R members solemnly agree to disclose to other representatives any potential conflict of interest related to his/her institution or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest.

3. In consultation with the Chairs, members are assigned to a group structuring GloPID-R work and coordination as followed:

   a. **Group 1 – Core group of Global Funders**: Funders with capacity for rapid funding during outbreaks (less than one month), unearmarked, global, without geographic constraint.

   b. **Group 2 – Larger group of Members**: Focusing on funding for research without a rapid mechanism in the case of an outbreak, without geographic restriction, with funding limited to specific national teams globally deployed, funding either research response or preparedness.

   c. **Group 3 – National funders**: Key group, funding national or regional research activities (including countries facing and responding at the frontline to outbreaks).

   d. **Geographic groups**: In addition to the above groups, members from the same region are invited to take part in a geographic group for specific activities based on regional priorities. One member, designated by the Chairs or the General Assembly, leads the structuration and the management of its regional group.

4. Additionally, members are invited to participate to thematic working groups decided by the General Assembly and/or the Chairs. These groups work on a thematic or a disease, guided by ToRs with timelines, deliverables and an accountability mechanism.

5. Public health institutions, regulatory agencies, or other organizations that are not funding organizations may be invited as observers. Their participation as observer shall be proposed by a Member to the General Assembly and approved by it. Following this approval, participation in specific GloPID-R meetings and activities shall be at the discretion of the Chair.

6. Companies and industry associations engaged in research related to new or re-emerging infectious diseases may be invited to participate in GloPID-R activities and discussions as observers without voting rights through a specific Industry Stakeholder Group (ISG).

II - General Assembly

7. The General Assembly is the decision-making body of GloPID-R.

8. It shall, in any case, take all decisions related to:
   - GloPID-R’s priorities, objectives and projects;
   - GloPID-R’s communication plan;
   - GloPID-R’s ethics and conflict of interest policy;
   - work programme of the Secretariat;
   - validation of the Strategy;
- validation and implementation of the Response Plan; creation of specific committees or governance bodies;
- modification of the GloPID-R Charter or its annexes;
- any other significant decisions.

9. The General Assembly shall consist of all GloPID-R Members. Members may participate with up to three representatives in the General Assembly, but each member shall only have one vote in the General Assembly.

10. Every two years, the General Assembly shall elect its Chair and Vice-Chairs amongst the representatives of its Members. The mandate is for a duration of two years, renewable without limit of consecutive terms. The organization elected prevails to its individual representative, and its mandate continues in case it changes its representative.

11. The Chair shall be responsible to convene ordinary and extraordinary meetings of the General Assembly, to represent the GloPID-R initiative and network and to follow-up on all projects decided by the General Assembly in-between ordinary and extraordinary meetings. The Chair may also delegate the task of follow-up on projects to the GloPID-R Secretariat.

12. In between face-to-face meetings of the General Assembly, its Members may also deliberate and take decisions by audioconference, videoconference or e-mail.

13. The Chair shall prepare and send a written agenda for the General Assembly no later than two weeks preceding the General Assembly. The Chair may also delegate this task to the GloPID-R Secretariat. During a meeting of the General Assembly, the Members may also agree to add a new item to the original agenda.

14. When decisions are proposed to the General Assembly, consensus of the representatives of its Members should be sought on the issues discussed. However, if a consensus cannot be reached, decisions may in exceptional cases be taken by the simple majority of all Members. The comments of Members not represented at the General Assembly will generally (except in cases of extreme urgency) be sought on decisions proposed by the General Assembly before its decisions become final.

All representatives of GloPID-R Members shall disclose to other representatives any potential conflict of interest related to his/her institution or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest. All representatives also agree to withdraw from the discussion if such a conflict of interest arises and if requested to do so by the other representatives after the situation has been disclosed.

15. The Chair shall produce or ask the Secretariat to produce written conclusions of the General Assembly, which, after their adoption by the members present, shall constitute the formal record of all decisions taken.

III- Industry Stakeholder Group (ISG)

16. The GloPID-R ISG is open to all companies and industry associations engaged in research related to new or re-emerging infectious diseases and sharing the vision, objectives and commitments expressed in the Charter.

17. Each company/industry association in the ISG shall participate in discussions through a single representative, which may be changed by informing the GloPID-R Chair in writing.

18. Members of the ISG will be invited by the Chair of GloPID-R to participate in General Assemblies, teleconferences, extraordinary meetings, specific working groups, workshops or other GloPID-R activities, unless the related discussions are specifically restricted to GloPID-R members. Members of the ISG will participate as observers without voting rights.
When required, the Chair of GloPID-R may limit the participation of the ISG to one representative, namely the Chair of the ISG or a designated replacement.

19. Members of the ISG shall withdraw from discussions if a conflict of interest arises and if requested to do so by other participants in the discussion or by the GloPID-R Chair.

IV- Secretariat

20. The Secretariat supports the implementation of the GloPID-R objectives in close collaboration with the General Assembly, its Chair and Vice-Chairs and the different committees created.

21. The Secretariat shall generally participate in all meetings of the General Assembly without a vote. The Assembly may decide to discuss certain agenda items without the Secretariat.

22. The tasks of the Secretariat shall include (i) organizational support to the functioning of the GloPID-R network such as the organization of General Assembly meetings, information exchange amongst Members, external representation of the initiative and external communication operations, as well as (ii) the direct implementation of actions to achieve GloPID-R’s objective.

23. The tasks of the Secretariat shall be detailed in an annual work programme to be presented and approved by the General Assembly.

24. The Secretariat shall submit regular updates on its activities to the Chair and Vice-Chairs of the General Assembly. The Secretariat will also regularly inform and discuss its activities with the Scientific Advisors.

All GloPID-R Secretariat members shall abide to the conflict of interest policy presented in Annex V.

V- Scientific Advisors

25. Two Scientific Advisors will be assigned by the Chairs to advise the General Assembly, the Chair and Vice-Chairs as well as the Secretariat on all scientific issues relevant to GloPID-R. The Scientific Advisors are nominated by the Chairs for a period of 2 years renewable.

26. One of the two scientific advisors shall attend Chair’s meeting and teleconference to advise on any scientific issue. The two scientific advisors shall also attend Members teleconference and the General Assembly.

27. The Scientific Advisors shall provide advice on GloPID-R activities and in the subsequent discussions on findings, ideas and possible solutions. They support the activities of the scientific working group within GloPID-R, and shall also support the development of a scientific and technical Strategic agenda.

28. The Scientific Advisors work in close collaboration with the WHO expert groups related to research in emerging outbreak to reinforce alignment in policy priority and policy development between GloPID-R and WHO.

29. The Scientific Advisors are experts covering the relevant fields invested by GloPID-R. The work of the Scientific Advisors shall be complemented as needed by additional experts identified by the Secretariat or Members in agreement with the Chair and Vice-Chairs, based on the needs identified.

30. The Scientific Advisors may decide to consult additional external experts, including other stakeholders, such as public health actors, the veterinary sectors, regulatory, legal and ethical institutions and experts and civil society organizations. All experts called for an advisory role in GloPID-R are requested to disclose any circumstance that could represent a potential conflict of interest related to the activity in which they will be involved. All experts (including the Scientific Advisors) will therefore sign a declaration of interest (presented in Annex IV of the Charter) to be reviewed by the
Chair/Vice-Chairs of GloPID-R (or a specific Ethics Committee to be established by the GloPID-R Assembly). The GloPID-R Secretariat will keep these declarations of interest in a specific registry.

VI- Working relations between GloPID-R bodies

31. In between ordinary and extraordinary Assembly meetings, the Chair and Vice-Chairs should ensure regular coordination among themselves in relation to the pursuit of the GloPID-R objectives and the implementation of Assembly decisions.

32. In between ordinary and extraordinary Assembly meetings, interactions relating to the activities and tasks of the Secretariat should take place between the Chair and Vice-Chairs and the Secretariat on a regular basis, preferably during the meetings and audioconferences of the Chair and Vice-Chairs. Updates on the work of the Secretariat should be principally discussed on this occasion to limit excessive reporting.

33. In between ordinary and extraordinary Assembly meetings, the Chairs are following and supporting members leading regional groups with any needed support, and thematic groups with support of the scientific advisor.

34. Some Chairs are the focal point of the Board of Chair on one specific subject (such as some scientific and thematic one, regional approach, advocacy & communication ...). They interact directly with the Secretariat and members and report to the other Chairs regularly.

VI- Withdrawal

35. A Member may always exercise a withdrawal right and propose to its Representative the permanent withdrawal of its organization.

36. Such a withdrawal will be immediately effective following written information of the Chair. Information about this withdrawal will be shared amongst all Members.
Annex III – Declaration of interest for GloPID-R Members

PREAMBLE

1. The goal of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) is to facilitate an effective research response within 48 hours of a significant outbreak of a new or re-emerging infectious disease with pandemic potential, in order to save lives and economies worldwide. To achieve this goal the GloPID-R network brings together funding bodies investing in research to ensure that research capacity and capabilities are in place to support the conduct of scientific research related to new or re-emerging infectious diseases.

2. As stated in the GloPID-R Charter (cf. “Ethics and conflict of interest policy”), all institutions or persons participating in GloPID-R activities agree to participate in good faith and act with the highest ethical and moral standards. Specifically, by signing the GloPID-R Charter, all representatives of GloPID-R Members have solemnly agreed to disclose to other representatives any potential conflict of interest related to his/her institution or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest. All representatives have also agreed to withdraw from the related discussions if such a conflict of interest arises and if requested to do so by the other representatives.

3. The purpose of the attached Declaration of interest (DOI) form is to support this requirement, ensure trust in GloPID-R and between its members, and protect the integrity and reputation of GloPID-R discussions and decision-making processes.

DEFINITIONS

4. A conflict of interest is any interest, which may affect, or may reasonably be perceived to affect, the member’s objectivity and opinion.

5. Affirmative answers to the questions in the DOI form do not automatically constitute a conflict of interest or disqualify or limit participation in GloPID-R discussions. But interests should be disclosed in good faith in order to ensure transparency and trust between GloPID-R members.

6. Whenever a GloPID-R member becomes aware at any time that new interests should be disclosed or that a conflict of interest arises, could be perceived to arise, or is reasonably likely to arise, it must disclose this new interest or element promptly.

7. A register will be established to record all actual or perceived conflict of interest, and the actions taken to address these. The register will be monitored and updated by the GloPID-R Secretariat, and accessible to any GloPID-R member on request.
Declaration of interest

Organization name: 
Country: 
Name of Representative: 
Position of Representative: 
Email: 
Telephone: 

1. Commercial activities

Is your organization, any subsidiary or related institution or entity, involved in selling a product/solution or offering paid services in a field directly related to GloPID-R work or to the topic(s) discussed? Is it planning to develop such product/solution or such services?

☐ YES / ☐ NO

Please list the related activities, detailing their nature, client(s), legal vehicle used to provide the products/solutions/services, as well as information on related revenues:

☐ If more practical, please provide the list on a separate document.

<table>
<thead>
<tr>
<th>Activities</th>
<th>Client(s)</th>
<th>Legal vehicle used</th>
<th>Revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Investments & other financial interests

Has your organization, any subsidiary or related institution or entity, made any investment in a commercial project or commercial entity with an interest directly related to GloPID-R work or to the topic(s) discussed? Is it currently planning to invest in such a commercial project or commercial entity?

☐ YES / ☐ NO

Please list the related investments (including indirect investments through trust or holding companies, and excluding mutual funds, pension funds, or similar structures that are broadly diversified):

☐ If more practical, please provide the list on a separate document.

<table>
<thead>
<tr>
<th>Area concerned</th>
<th>Nature of investment</th>
<th>Volume of investment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
If the related investment is covered by a non-disclosure agreement or if you consider a simple disclosure would have a substantial adverse impact on the related business or company interests, please explain the area concerned and state that you do not wish to disclose any information further, but will systematically withdraw from any discussion directly or indirectly related to the field of activity.

3. Intellectual Property

Has your organization, any subsidiary or related institution or entity, current intellectual property rights or technology right-of-use* that might be enhanced or diminished by the outcome of GloPID-R work?

*Patents, trademarks, copyrights or right-of-use related to specific technologies or technological platforms

☐ YES / ☐ NO

Please list the related property rights:

<table>
<thead>
<tr>
<th>Property rights concerned</th>
<th>Nature of related GloPID-R activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If more practical, please provide the list on a separate document.

4. Origin of financial resources

Has your organization, any subsidiary or related institution or entity, received direct financial support or funding from another GloPID-R member or a member of its Industry Stakeholder Group (ISG) in the past two years?

*Financial support includes direct budgetary support, grants, sponsorships, as well as provision of equipment or facilities

☐ YES / ☐ NO

Please list the support or funding received and the topic(s) concerned:

☐ If more practical, please provide the list on a separate document.

☐ If applicable, please also disclose any current negotiation for future support or funding.
<table>
<thead>
<tr>
<th>Nature of support received (or being negotiated)</th>
<th>Annual volume of financial support</th>
<th>Rationale and objective(s)</th>
<th>GloPID-R or ISG funding organization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. Other institutional interests

Are there other aspects of your organization’s work or present circumstances not addressed above that might be perceived as affecting its objectivity?

☐ YES / ☐ NO

Please detail as needed:

6. Individual interests of the representative

Apart from the interests related to the institution you represent and that are stated above, are there any additional individual interests (scientific, financial or personal) that may affect your own involvement, opinion and work within GloPID-R and/or could lead to a conflict of interest?

☐ YES / ☐ NO

Please detail as needed:

☐ We have no conflict of interest to report.

I hereby declare that the information set forth above is true and complete to the best of my knowledge. Should there, at any time during my engagement with GloPID-R, be any change to the above information, I will promptly notify the GloPID-R Secretariat and complete a new declaration of interests, which describes the changes.

I have read the GloPID-R Ethics and conflict of interest policy and hereby agree to its terms.

Date: Position:

Signature:
Annex IV – Declaration of interest for GloPID-R experts

PREAMBLE

GloPID-R activities on global health and medical research issues require the assistance of experts to provide *ad hoc* expertise and/or to participate in permanent work groups or advisory councils (such as its Scientific Advisory Board). These experts may have interests related to their expertise. To ensure the highest integrity and public confidence in its activities, GloPID-R requires that these experts serving in an advisory role disclose any circumstances that could give rise to a potential conflict of interest related to the subject of the activity in which they will be involved.

All experts called for an advisory role must disclose any circumstance that could represent a potential conflict of interest (i.e., any interest that may affect, or may reasonably be perceived to affect, the expert’s objectivity and independence).

In addition, when working for GloPID-R:

1. All experts shall work independently, in a personal capacity and not on behalf of any organisation.

2. All experts shall:

   a. handle the subject for which they are providing expertise in a *confidential and fair* way,

   b. assist to the best of their abilities, professional skills and knowledge, while *applying the highest ethical and moral standards*,

   c. follow instructions and time-schedules given by the GloPID-R Chairs and Vice-Chairs and deliver consistently high quality work.

3. If a legal entity approaches the expert during her/his advisory role, he/she shall immediately inform the GloPID-R Chairs and Vice-Chairs (or any GloPID-R Ethics Committee established by the GloPID-R Assembly).

4. All experts shall perform her/his work *impartially*.

All experts called for an advisory role or serving in an advisory role accept that the GloPID-R Chair and Vice-Chairs (or any GloPID-R Ethics Committee established by the GloPID-R Assembly) have the permanent right at their discretion to recuse them if they believe a potential conflict of interest would have an adverse impact on their work, opinion or activity for GloPID-R. Neither GloPID-R, nor its Chair, Vice-Chairs and Members may be held liable in the case an expert is recused.
DECLARATION

As an expert called by GloPID-R, you must disclose on this Declaration of Interest (DOI) form any financial, professional or other interest relevant to the subject of the expert group, work or meeting in which you have been asked to participate in or contribute towards and any interest that could be affected by the outcome of the meeting or work. You must also declare relevant interests of your immediate family members and, if you are aware of it, relevant interests of other parties with whom you have substantial common interests and which may be perceived as unduly influencing your judgement (e.g. employer, close professional associates, administrative unit or department).

Please complete this form and submit it to the GloPID-R Secretariat.

Your answers will be reviewed by the GloPID-R Chair and Vice-Chairs or by a specific Ethics Committee (if such a Committee is established by the GloPID-R Assembly), as well as by the Scientific Advisory Board Chair to determine whether you have a conflict of interest relevant to the subject at hand.

They may conclude that no potential conflict exists or that the interest is irrelevant or insignificant or would not have an adverse impact on your work, opinion or activity. On the other hand, they may decide that you should be recused from participating in the expert group, meeting or work concerned, after consulting with you. The decision is a permanent right at their discretion and shall not be contested.

Name:
Institution:
Email:

Date and title of meeting or work, including description of subject matter to be considered:

EMPLOYMENT AND CONSULTING

Within the past 4 years, have you received remuneration from a commercial entity or other organization with an interest related to the subject of the meeting or work?

1a Employment
1b Consulting, including service as a technical or other advisor

RESEARCH SUPPORT

Within the past 4 years, have you or has your research unit received support from a commercial entity or other organization with an interest related to the subject of the meeting or work?

2a Research support, including grants, collaborations, sponsorships, and other funding
2b Non-monetary support valued at more than US $1000 overall (include equipment, facilities, research assistants, paid travel to meetings, etc.)

Support (including honoraria) for being on a speakers bureau, giving speeches or training for a commercial entity or other organization with an interest related to the subject of the meeting or work?
INVESTMENT INTERESTS

Do you have current investments (valued at more than US $5,000 overall) in a commercial entity with an interest related to the subject of the meeting or work? Please also include indirect investments such as a trust or holding company. You may exclude mutual funds, pension funds or similar investments that are broadly diversified and on which you exercise no control.

3a Stocks, bonds, stock options, other securities (e.g., short sales)  Yes  No
3b Commercial business interests (e.g., proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company)  Yes  No

INTELLECTUAL PROPERTY

Do you have any intellectual property rights that might be enhanced or diminished by the outcome of the meeting or work?

4a Patents, trademarks, or copyrights (including pending applications)  Yes  No
4b Proprietary know-how in a substance, technology or process  Yes  No

PUBLIC STATEMENTS AND POSITIONS (during the past 3 years)

5a As part of a regulatory, legislative or judicial process, have you provided an expert opinion or testimony, related to the subject of the meeting or work, for a commercial entity or other organization?  Yes  No
5b Have you held an office or other position, paid or unpaid, where you represented interests or defended a position related to the subject of the meeting or work?  Yes  No

+ + +

EXPLANATION OF "YES" RESPONSES: If the answer to any of the above questions is "yes", check above and briefly describe the circumstances on the below table.

Nos. 1 - 4: Type of interest, question number and category (e.g., Intellectual Property 4.a copyrights) and basic descriptive details.

<table>
<thead>
<tr>
<th>Name of company, organization, or institution</th>
<th>Belongs to you, a family member, employer, research unit or other?</th>
<th>Amount of income or value of interest</th>
<th>Current interest (or year ceased)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Write here</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Nos. 5: Describe the subject, specific circumstances, parties involved, time frame and other relevant details

Write here

DECLARATION, I hereby declare on my honour that the disclosed information is true and complete to the best of my knowledge.

Date:

Signature:
Annex V – Conflict of interest policy for GloPID-R Secretariat

PREAMBLE

Any Individual or entity (hereafter a “person”) working permanently or temporarily for the GloPID-R Secretariat, whatever its status, will strive to avoid any conflict of interest between the interests of GloPID-R on the one hand, and personal and institutional interests on the other.

The purposes of this policy is to protect the integrity of the GloPID-R’s decision-making process, to enable the GloPID-R stakeholders to have confidence in the integrity of GloPID-R, and to protect the integrity and reputation of volunteers, the GloPID-R Secretariat and GloPID-R members.

Examples of conflicts of interest include:

1. A GloPID-R Secretariat member who is also, through his/her membership in another network or organisation, or as a person employed or contracted by institutions that constitute and operate the GloPID-R Secretariat, involved with a grant proposal while the relevant funding initiative is being discussed within GloPID-R ahead of publication by one or more GloPID-R members.

2. A GloPID-R Secretariat member who is also, through his/her membership of another network or organisation, or as a person employed or contracted by institutions that constitute and operate the GloPID-R Secretariat, involved with a grant proposal for which changes or alterations to the relevant funding initiative are discussed within GloPID-R following publication by one or more GloPID-R members.

Any person working permanently or temporarily for the GloPID-R Secretariat, whatever its status will therefore make a full, written disclosure of interests, such as relationships and posts held that could potentially result in a conflict of interest. This written disclosure will be kept in the register of Secretariat documents and it will be updated as appropriate. It will always be kept available to the GloPID-R Chair or Vice-Chairs upon simple request.

A full disclosure of interests was made for named staff members in the original proposal developed for the GloPID-R Secretariat by Fondation Mérieux (FMX) and the University of Oxford (UOXF).

In addition, in the course of GloPID-R related meetings or activities, GloPID-R Secretariat members will verbally disclose any interests in a decision where there may be a conflict between GloPID-R's best interests and the GloPID-R Secretariat members’ best interests or a conflict between the best interests of two organisations that the GloPID-R Secretariat members are involved with. If a conflict of interest is discovered before the meeting or activity, written disclosure can be made by email to the meeting organiser(s).
DECLARATION

After disclosure such as described in the Preamble above, I understand that I may be asked to leave the room for the discussion and may not be able to listen in on the discussion or take part in any decisions or deliberations depending on the judgement of the GloPID-R members present at the time.

Any such disclosure and the subsequent actions taken will be noted in the minutes.

This policy is meant to supplement good judgment, and GloPID-R Secretariat members, volunteers and GloPID-R members should respect its spirit as well as its wording.

Name:

Date Adopted: ______________________

Signature: ________________________
Appendix: Declaration of Interests for GloPID-R Secretariat members.

GloPID-R Secretariat

Register of Members’ Interests

Declaration of Interest

<table>
<thead>
<tr>
<th>Name and organisation</th>
<th>Role in the GloPID-R Secretariat</th>
<th>Nature of relationship and/or nature of conflict of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This declaration of interest is made in accordance with the GloPID-R Secretariat Conflict of Interest Policy.

Name………………………………………..

Position …………………………………..

Signed …………………………………….

Date ……………………………………….

Note: Complete one form for each newly appointed GloPID-R Secretariat member and file with the minutes.
Annex VI – Conflict of interest policy for GloPID-R ISG

PREAMBLE

1. The goal of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) is to facilitate an effective research response within 48 hours of a significant outbreak of a new or re-emerging infectious disease with pandemic potential, in order to save lives and economies worldwide. To achieve this goal the GloPID-R network brings together funding bodies investing in research to ensure that research capacity and capabilities are in place to support the conduct of scientific research related to new or re-emerging infectious diseases.

2. To help achieve its objective, the GloPID-R network has decided to create an Industry Stakeholder Group (ISG) that brings together companies and industry associations engaged in research related to new or re-emerging infectious diseases, in order to ensure dialogue and coordination of efforts between for-profit and not-for-profit funders of outbreak research.

3. As stated in the GloPID-R Charter (cf. “Ethics and conflict of interest policy”), all entities or persons participating in GloPID-R activities agree to participate in good faith and act with the highest ethical and moral standards. Specifically, by joining the Industry Stakeholder Group (ISG), companies and industry associations solemnly agree to disclose any potential conflict of interest related to his/her entity or himself/herself whenever a GloPID-R issue or topic of discussion may raise such a conflict of interest.

4. Given the nature of GloPID-R activities, participating organizations in the Industry Stakeholder Group (ISG) may indeed have varying degrees of conflict of interest. The purpose of this Conflict of interest policy and Declaration of interest form is therefore to ensure trust in GloPID-R and between all stakeholders and to protect the integrity and reputation of GloPID-R discussions and decision-making processes.

PRINCIPLES FOR MANAGING CONFLICT OF INTEREST

5. To ensure the highest integrity and public confidence, GloPID-R requires that all participants in the Industry Stakeholder Group (ISG) shall disclose any circumstance that could give rise to a potential conflict of interest related to GloPID-R or the subjects of discussion or decision-making process in which they will be involved in GloPID-R. This disclosure should be made using the following Declaration of interest (DOI) form (see appendix).

6. A conflict of interest is any interest, which may affect, or may reasonably be perceived to affect the participant’s objectivity and opinion.

7. Affirmative answers to the questions in the DOI form do not automatically disqualify or limit participation in the Industry Stakeholder Group (ISG) and its related discussions. The Declaration of interest (DOI) form shall be reviewed by the GloPID-R Chair and Vice-Chairs or by a specific Ethics Committee (if such a Committee is established by the GloPID-R Assembly).
8. The GloPID-R Chair and Vice-Chairs may conclude that no potential conflict exists or that the interest is irrelevant or insignificant or would not have an adverse impact on the participating organization’s work, opinion or activity. On the other hand, they may decide that the organization should be recused from participating in the ISG or in a specific meeting or work group. The decision to refuse or limit the organization’s participation shall be made in any circumstance by the GloPID-R Chair and Vice-Chairs. The decision is a permanent right at their discretion and shall not be contested.

9. If the participating organization becomes aware at any time that a new conflict of interest arises, could be perceived to arise, or is reasonably likely to arise, it must disclose this new interest promptly to the GloPID-R Chair and Vice-Chairs, as soon as it is aware of this potential new conflict of interest.

10. A participating organization who is not able or willing to disclose details in the DOI form must disclose that a conflict of interest situation may exist, preventing it from participating, after which appropriate action will be decided by the GloPID-R Chair and Vice-Chairs.

11. A register will be established to record all actual or perceived conflict of interest, and the actions taken to address these, as identified by the processes described above. The register will be monitored and updated by the GloPID-R Secretariat, and accessible to the Chair and Vice-Chairs of GloPID-R on request.
Declaration of interest

Organization / Company name:  
Country:  
Name of Representative:  
Position of Representative:  
Email:  
Telephone:  

1. Research

Has your organization, any subsidiary, or the parent company to which your organization belong received research support or funding* from a GloPID-R member in the past two years on a topic directly related to GloPID-R work or to the topic(s) discussed by the ISG?

*Research support or funding include grants, sponsorships, as well as provision of equipment or facilities

☐ YES / ☐ NO

Please list the support or funding received and the topic(s) concerned:

☐ If more practical, please provide the list on a separate document.

☐ If applicable, please also disclose any current negotiation for future support or funding.

<table>
<thead>
<tr>
<th>Research area</th>
<th>Project concerned</th>
<th>Support received (or being negotiated)</th>
<th>GloPID-R funding organization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Investments

Has your organization, any subsidiary, or the parent company to which your organization belong, developed a product/solution or invested in a project or commercial entity with an interest directly related to GloPID-R work or to the topic(s) discussed? Is it currently planning to develop such a product/solution or invest in such a project or commercial entity?

☐ YES / ☐ NO

Please list the related investments (including indirect investments through trust or holding companies, and excluding mutual funds, pension funds, or similar structures that are broadly diversified):

☐ If more practical, please provide the list on a separate document.
### 3. Intellectual Property

Has your organization, any subsidiary, or the parent company to which your organization belong, any current intellectual property rights** that might be enhanced or diminished by the outcome of your work with GloPID-R or the ISG?

**Patents, trademarks, copyrights or technologies

- [ ] YES / [ ] NO

Please list the related property rights:

<table>
<thead>
<tr>
<th>Property rights concerned</th>
<th>Nature of related GloPID-R activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- [ ] If more practical, please provide the list on a separate document.

If the related investment is covered by a non-disclosure agreement or if you consider a simple disclosure would have a substantial adverse impact on your business or company interests, please simply indicate the topic concerned and state that you do not wish to disclose any information further.
4. Other interests of your organization

Are there other aspects of your organization’s work or present circumstances not addressed above that might be perceived as affecting its objectivity?

☐ YES / ☐ NO

Please detail as needed:

5. Individual interests of the representative

Apart from the interests related to the organization you represent and that are stated above, are there any additional individual interests (scientific, financial or personal) that may affect your involvement, opinion and work within GloPID-R and/or could lead to a conflict of interest?

☐ YES / ☐ NO

Please detail as needed:

☐ We have no conflict of interest to report.

I hereby declare that the information set forth above is true and complete to the best of my knowledge. Should there, at any time during my engagement with GloPID-R and the ISG, be any change to the above information, I will promptly notify the GloPID-R Secretariat and complete a new declaration of interests, which describes the changes.

I have read and hereby agree to the terms of the GloPID-R ISG “Conflict of interest policy”.

Date: Position:

Signature: